Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours [Phase 1]

View source ↗

Summary

This document provides an update on a Phase 1 clinical trial evaluating ETC-1922159 as a single agent and in combination with pembrolizumab in patients with adv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• ETC-1922159
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: EDDC (Experimental Drug Development Centre), A*STAR Research Entities | Conditions: Solid Tumors | Phase 1 | Status: ACTIVE_NOT_RECRUITING